Million-dollar investment from Eir Ventures will bring Swedish cancer company to clinic
Life science fund Eir Ventures leads a SEK 45m (USD 4.8m) financing round meant to bring Swedish cancer company Strike Pharma’s first drug candidate closer to human clinical trials.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Swedish biotech firm Strike Pharma has secured financial backing to further advance its antibody-based technology for the development of individualized immunotherapeutic treatments for cancer and to bring its first candidate to clinic.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Set-in-stone criteria will reduce risk for new biotech fund
For subscribers
